Skip to main content

Table 3 Common adverse events reported during either 12-week treatment period

From: Cannabinoid treatment for autism: a proof-of-concept randomized trial

  Whole-plant extract
CBD 5.5 mg/kg/d; n = 95 (%)
Pure cannabinoids
CBD 5.5 mg/kg/d; n = 93 (%)
Placebo
n = 94 (%)
P value (placebo vs cannabinoids)
Somnolence 27 24 7.5  < 0.001
Mild 20 18.5 7.5  
Moderate 7 5.5 0  
Severe 0 0 0  
Decreased appetite 24 22 15 0.157
Mild 21 16.5 13  
Moderate 3 5.5 2  
Severe 0 0 0  
Weight loss 12 13 4 0.053
Mild 9 12 3  
Moderate 3 1 1  
Severe 0 0 0  
Tiredness 25 34 19 0.077
Mild 21 28.5 18  
Moderate 4 5.5 1  
Severe 0 0 0  
Euphoria 20 19 13 0.201
Mild 15 16 12  
Moderate 5 3 1  
Severe 0 0 0  
Anxiety 20 27 14 0.084
Mild 17 25 11  
Moderate 3 2 3  
  1. CBD: cannabidiol (CBD:THC ratio was 20:1 for both cannabinoids tested; the average daily dose per kg was lower than the target dose as many participants weighted over 42 kg and reached the maximal daily dose)
  2. Bold: sum of mild + moderate + severe for each adverse event